Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivoglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 0.98 |
| ▸ | ESRRA | P11474 | 1/20 | 0.72 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.62 |
| ▸ | PPARA | Q07869 | 6/20 | 0.62 |
| ▸ | MPC2 | O95563 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivoglitazone SCHEMBL6064788 | 1.00 | PPARG (0.98) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL2906120 | 0.99 | PPARG (1.00) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL143498 | 0.99 | PPARG (1.00) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL5319250 | 0.99 | PPARG (1.00) | PPARGESRRAFFAR1PPARAMPC2 | |
| Rivoglitazone SCHEMBL4885815 | 0.95 | PPARG (0.91) | PPARGESRRAFFAR1PPARAMPC2 | |
| Hydrochloric Acid SCHEMBL6544473 | 0.95 | PPARG (0.88) | PPARGESRRAFFAR1PPARAMPC2 | |
| SCHEMBL6543624 | 0.94 | PPARG (0.90) | PPARGESRRAFFAR1PPARAMPC2 | |
| SCHEMBL15730390 | 0.93 | PPARG (0.88) | PPARGESRRAFFAR1PPARAMPC2 | |
| Hydrochloric Acid SCHEMBL6701457 | 0.92 | PPARG (0.83) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL6896700 | 0.92 | PPARG (0.86) | PPARGESRRAFFAR1PPARAMPC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092555-A1 | Thiazolidinedione compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-21 | — | — | US | claimed |
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-02 | — | — | US | claimed |
| EP-1990053-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ADIPONECTIN PRODUCTION | Daiichi Sankyo Company, Limited (JP) | 2008-11-12 | — | — | EP | claimed |
| US-20080262054-A1 | incorporating cellulose, a cellulose derivative, a polyvinyl alcohol derivative, a polyvinyl alcohol derivative mixture or a mixture thereof with 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}thiazolidine-2,4-dione; superior solubility; improving insulin resistance; lowering blood glucose | KAWASAKI TAKAO | 2008-10-23 | — | — | US | claimed |
| US-20080103185-A1 | Process for Producing Thiazolidinedione Compound and Production Intermediate Thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-01 | — | — | US | claimed |
| EP-1902713-A1 | PHARMACEUTICAL COMPOSITION CONTAINING THIAZOLIDINEDIONE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-03-26 | — | — | EP | claimed |
| EP-1894929-A1 | PROCESS FOR PRODUCING THIAZOLIDINEDIONE COMPOUND AND PRODUCTION INTERMEDIATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-03-05 | — | — | EP | claimed |
| US-20070287685-A1 | Medicinal composition containing FBPase inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1825854-A1 | MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2007-08-29 | — | — | EP | claimed |
| US-20020111373-A1 | Hydrochloride salt of a fused heterocyclic compound | SANKYO COMPANY, LIMITED (JP) | 2002-08-15 | — | — | US | claimed |
| US-20110092555-A1 | Thiazolidinedione compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110092555-A1 | Thiazolidinedione compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2226321-A2 | Process for producing thiazolidinediones and intermediates thereof | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-20090137626-A1 | Pharmaceutical Composition Containing PPARgamma Agonist | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090124626-A1 | Pharmaceutical agent comprising insulin resistance improving agent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1191019-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZIMIDAZOLE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | Sankyo Company, Limited (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1180519-A1 | HYDROCHLORIDE OF FUSED-HETEROCYCLE COMPOUND | Sankyo Company, Limited (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| JP-2001039976-A | HYDROCHLORIDE OF CONDENSED HETEROCYCLIC COMPOUND | SANKYO CO LTD | 2001-02-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092555-A1 | Thiazolidinedione compound | GLP1R, DPP4, KCNK4 | PPARG 209/4885ESRRA 1626/4885FFAR1 2235/4885 |
| US-20080262054-A1 | incorporating cellulose, a cellulose derivative, a polyvinyl alcohol derivative, a polyvinyl alcohol derivative mixture or a mixture thereof with 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}thiazolidine-2,4-dione; superior solubility; improving insulin resistance; lowering blood glucose | SLC5A2, SLC5A1, INSR | PPARG 419/4885ESRRA 3361/4885FFAR1 1293/4885 |
| US-20090124626-A1 | Pharmaceutical agent comprising insulin resistance improving agent | DPP4, DPP7, IAPP | PPARG 135/4885ESRRA 575/4885FFAR1 424/4885 |
| US-20090137626-A1 | Pharmaceutical Composition Containing PPARgamma Agonist | PPARG, PPARA, PPARD | PPARG 1/4885ESRRA 88/4885FFAR1 21/4885 |
| US-20080103185-A1 | Process for Producing Thiazolidinedione Compound and Production Intermediate Thereof | INSR, GCKR, GPR119 | PPARG 28/4885ESRRA 863/4885FFAR1 92/4885 |
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | ADIPOR1, ADIPOR2, FABP4 | PPARG 37/4885ESRRA 453/4885FFAR1 247/4885 |
| US-20020111373-A1 | Hydrochloride salt of a fused heterocyclic compound | SLC5A1, SLC5A2, SLC2A8 | PPARG 1242/4885ESRRA 4462/4885FFAR1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.